Intuitive Surgical, Inc (NASDAQ:ISRG): Leading Healthcare Stock to Look out for February 14, 2023

Intuitive Surgical, Inc (NASDAQ:ISRG): Leading Healthcare Stock to Look out for

On 1 Feb 2023, the Federal Reserve raised interest rates by 0.25%, bumping the federal funds rate to a target range of 4.5- 4.75%. With this move, it was the Fed’s 8th consecutive interest rate hike in efforts to rapidly reduce liquidity in the financial markets, tamping down high inflation rates. [1]

Generally speaking, almost everyone has been affected by the high interest rates, either directly or indirectly. The interest rate hike has affected the aggregate demand in the market, slowed down the economy. The US stock market was no exception, with the S&P 500 dropping from approximately 4,600 points to 4,000 ever since the start of the interest rate hikes. Undeniably we are in a bear market right now due to the high interest rate environment. In this market downturn, it is time for investors (especially long-term investors) to look for a potential stock that has strong fundamental worth.

Healthcare industry: US surgical robots market

With quantitative tightening and rising interest rates, we need to look for an industry that can thrive in this market downturn. The healthcare industry could be one viable option. Known as a defensive sector, the demand for healthcare is typically not affected extensively by economic conditions, as everyone would still require medical treatment for an illness regardless of the macroeconomic environment.

Furthermore, the healthcare industry is changing immensely as it seeks to improve care quality. Minimally-invasive surgeries hold massive potential as they are considered the best alternative as opposed to open surgeries.

We expect the rising demand for surgical robotic systems to continue in the future, with the implementation of technological innovations and advancements in minimally-invasive surgical procedures. In addition, the US surgical robots market are still considered a blue-ocean sector as there are not too many players involved in this industry.

According to the Grand View research, the US surgical robots market is predicted to have a compound annual growth rate of 17.9% from 2022 to 2030.

Intuitive Surgical, Inc (NASDAQ:ISRG): Leading Healthcare Stock to Look out forSource: Grand View Research [2]

Intuitive Surgical, Inc. (NASDAQ:ISRG)

Intuitive Surgical, Inc. (Nasdaq:ISRG) is one of the key players which specialise in the robotic-assisted surgery device market. It holds the highest market share in the industry.

As a pioneer and global technology leader in developing manufacture and marketing of robotic-assisted surgery products, it also has one of the largest moats and best fundamentals with almost 3 decades in the sector.

ISRG was the first company to have its robotic-assisted surgery device, the Da Vinci Surgical System, cleared by the US Food and Drug Administration (FDA) for the market.

The Da Vinci Surgical system allows surgeons to perform minimally-invasive surgeries, significantly benefiting patients. As compared to traditional open procedures, minimally-invasive ones result in less scarring, less bleeding, shorter hospital stays and faster recovery.

Strong brand stickiness

ISRG has strong brand stickiness as it is trusted and reliable. Furthermore, there are also very few substitutes available in the market. Currently, ISRG could be one of the best robotic-assisted surgery devices in the market. With quality comes price (USD 500,000 – 2 mil), it is highly unlikely for a customer to switch out of ISRG once committed.

Furthermore, the complicated system requires a great amount of time and effort to maximise utility, discouraging customers from swapping to a substitute.


Intuitive Surgical, Inc (NASDAQ:ISRG): Leading Healthcare Stock to Look out forSource: ISRG [3]

We can see from the table above that ISRG has a healthy diversified revenue from selling products and services.

The revenue for ISRG is equally split, with 56% of its revenue derived from selling instruments and accessories and 44% derived from providing systems and services. With this relatively equal split, it is able to effectively diversify risk. Providing disposable accessories, systems and services play a significant role in generating profit. The disposable accessories, system and service that are required for the Da Vinci Surgical System act as a stabilizer for ISRG to generate continued profit from existing customers.

The ISRG business model has a powerful ecosystem which enables it to see exponential growth on their revenue. After purchasing the device, customers need to spend on disposable accessories, system maintenance and subscription to the services provided by ISRG. This continued spending provides ISRG with a strong and stable source of income that would keep it afloat even in bad economic situations, in the long run.

Intuitive Surgical, Inc (NASDAQ:ISRG): Leading Healthcare Stock to Look out forSource: Morningstar [4]

Looking at the revenue of ISRG from 2012 to 2022, its revenue has increased by 12.51% in the 10-year period, 16.12% in the 5- year period and 15.31% in the 3-year period.

ISRG has been performing well, as evident from its steadily increasing revenue (since 2015). However, revenues decreased by 2.68% in 2020, following the fall in demand for surgical procedures and shortage of manpower in the manufacturing facilities caused by the COVID-19 pandemic. Furthermore, the lockdowns and shutdowns in major markets across the globe negatively impacted the supply chain, restricting the manufacturing of surgical robots in 2020.

The robotic-assisted surgery market is expected to grow as there is a growing demand for automated instruments with high accuracy and less human effort since the COVID-19 pandemic. An increasing trend has been observed in automated instrument adoption after the normalisation of COVID-19. This may be due to the effect of the COVID-19 pandemic, during which many become more conscious about life-threatening viral infections and contamination.

Intuitive Surgical, Inc (NASDAQ:ISRG): Leading Healthcare Stock to Look out forSource: Tradingview [5]

Looking at ISRG’s profitability ratio, the fundamentals are relatively strong. ISRG has been performing very well for the past 7 years as their Return On Assets has been a minimal of 10 %. It has also shown a minimal 11% Return On Equity. Based on its Return On Assets, it is evident that assets have been efficiently used to generate profit.

ISRG also has a very strong Return on Invested Capital, gross margin and operating margin. Apart from this, ISRG has little long-term debt and its debt to asset ratio is 0.01.

High barrier to entry

ISRG dominates the robotic-assisted surgery device market, with nearly 80% market shares as it was the first to be approved by the US FDA.

The industry has a very high barrier to entry as other companies will need a lot of time and investment funds to create a robotic-assisted surgery device that can substitute the one ISRG already has in the market.

As such, ISRG is irreplaceable in the market, in the short run, making it a safe and stable investment. However, there are potential competitors, such as Johnson & Johnson and Medtronic.

According to Evaluate Vantage, Medtronic’s Hugo system is a close substitute to ISRG’s Da Vinci Surgical system in the Europe market. [6]


In short, the healthcare industry is worth looking at in this macroeconomic environment, especially the robot-assisted surgical robot market.

Intuitive Surgical is poised to benefit with revenue potentially amounting to billions of dollars. Although Intuitive Surgical has very strong fundamentals and a good business model, the stock is still considered a high-risk investment as it has a very high valuation and volatility.

The high valuation may not be sustained as competition increases. Investors should also consider the uncertainty of the macroeconomic environment and government healthcare schemes & subsidies as well, but the company is definitely worth considering.

How to Get Started With POEMS

As the pioneer of Singapore’s online trading, POEMS’s award-winning suite of trading platforms offers investors and traders more than 40,000 financial products across global exchanges.

Explore an array of US shares with brokerage fees as low as US$1.88 flat* when you open a Cash Plus Account with us today. Find out more here (terms and conditions apply).

Intuitive Surgical, Inc (NASDAQ:ISRG): Leading Healthcare Stock to Look out for

We hope that you have found value reading this article. If you do not have a POEMS account, you may visit here to open one with us today.

Lastly, investing in a community is much more fun. You will get to interact with us and other seasoned investors who are generous in sharing their experience and expertise.

In this community, you will be exposed to quality educational materials, stock analysis to help you apply the concepts, unwrap the mindset of seasoned investors, and even post questions.

We look forward to sharing more insights with you in our growing and enthusiastic Telegram community. Join us now!

For enquiries, please email us at



These commentaries are intended for general circulation. It does not have regard to the specific investment objectives, financial situation and particular needs of any person who may receive this document. Accordingly, no warranty whatsoever is given and no liability whatsoever is accepted for any loss arising whether directly or indirectly as a result of any person acting based on this information. Opinions expressed in these commentaries are subject to change without notice. Investments are subject to investment risks including the possible loss of the principal amount invested. The value of the units and the income from them may fall as well as rise. Past performance figures as well as any projection or forecast used in these commentaries are not necessarily indicative of future or likely performance. Phillip Securities Pte Ltd (PSPL), its directors, connected persons or employees may from time to time have an interest in the financial instruments mentioned in these commentaries. Investors may wish to seek advice from a financial adviser before investing. In the event that investors choose not to seek advice from a financial adviser, they should consider whether the investment is suitable for them.

The information contained in these commentaries has been obtained from public sources which PSPL has no reason to believe are unreliable and any analysis, forecasts, projections, expectations and opinions (collectively the “Research”) contained in these commentaries are based on such information and are expressions of belief only. PSPL has not verified this information and no representation or warranty, express or implied, is made that such information or Research is accurate, complete or verified or should be relied upon as such. Any such information or Research contained in these commentaries are subject to change, and PSPL shall not have any responsibility to maintain the information or Research made available or to supply any corrections, updates or releases in connection therewith. In no event will PSPL be liable for any special, indirect, incidental or consequential damages which may be incurred from the use of the information or Research made available, even if it has been advised of the possibility of such damages. The companies and their employees mentioned in these commentaries cannot be held liable for any errors, inaccuracies and/or omissions howsoever caused. Any opinion or advice herein is made on a general basis and is subject to change without notice. The information provided in these commentaries may contain optimistic statements regarding future events or future financial performance of countries, markets or companies. You must make your own financial assessment of the relevance, accuracy and adequacy of the information provided in these commentaries.

Views and any strategies described in these commentaries may not be suitable for all investors. Opinions expressed herein may differ from the opinions expressed by other units of PSPL or its connected persons and associates. Any reference to or discussion of investment products or commodities in these commentaries is purely for illustrative purposes only and must not be construed as a recommendation, an offer or solicitation for the subscription, purchase or sale of the investment products or commodities mentioned.

Contact us to Open an Account

Need Assistance? Share your Details and we’ll get back to you


This material is provided by Phillip Capital Management (S) Ltd (“PCM”) for general information only and does not constitute a recommendation, an offer to sell, or a solicitation of any offer to invest in any of the exchange-traded fund (“ETF”) or the unit trust (“Products”) mentioned herein. It does not have any regard to your specific investment objectives, financial situation and any of your particular needs. You should read the Prospectus and the accompanying Product Highlights Sheet (“PHS”) for key features, key risks and other important information of the Products and obtain advice from a financial adviser (“FA“) pursuant to a separate engagement before making a commitment to invest in the Products. In the event that you choose not to obtain advice from a FA, you should assess whether the Products are suitable for you before proceeding to invest. A copy of the Prospectus and PHS are available from PCM, any of its Participating Dealers (“PDs“) for the ETF, or any of its authorised distributors for the unit trust managed by PCM.  

An ETF is not like a typical unit trust as the units of the ETF (the “Units“) are to be listed and traded like any share on the Singapore Exchange Securities Trading Limited (“SGX-ST”). Listing on the SGX-ST does not guarantee a liquid market for the Units which may be traded at prices above or below its NAV or may be suspended or delisted. Investors may buy or sell the Units on SGX-ST when it is listed. Investors cannot create or redeem Units directly with PCM and have no rights to request PCM to redeem or purchase their Units. Creation and redemption of Units are through PDs if investors are clients of the PDs, who have no obligation to agree to create or redeem Units on behalf of any investor and may impose terms and conditions in connection with such creation or redemption orders. Please refer to the Prospectus of the ETF for more details.  

Investments are subject to investment risks including the possible loss of the principal amount invested. The purchase of a unit in a fund is not the same as placing your money on deposit with a bank or deposit-taking company. There is no guarantee as to the amount of capital invested or return received. The value of the units and the income accruing to the units may fall or rise. Past performance is not necessarily indicative of the future or likely performance of the Products. There can be no assurance that investment objectives will be achieved.  

Where applicable, fund(s) may invest in financial derivatives and/or participate in securities lending and repurchase transactions for the purpose of hedging and/or efficient portfolio management, subject to the relevant regulatory requirements. PCM reserves the discretion to determine if currency exposure should be hedged actively, passively or not at all, in the best interest of the Products.  

The regular dividend distributions, out of either income and/or capital, are not guaranteed and subject to PCM’s discretion. Past payout yields and payments do not represent future payout yields and payments. Such dividend distributions will reduce the available capital for reinvestment and may result in an immediate decrease in the net asset value (“NAV”) of the Products. Please refer to <> for more information in relation to the dividend distributions.  

The information provided herein may be obtained or compiled from public and/or third party sources that PCM has no reason to believe are unreliable. Any opinion or view herein is an expression of belief of the individual author or the indicated source (as applicable) only. PCM makes no representation or warranty that such information is accurate, complete, verified or should be relied upon as such. The information does not constitute, and should not be used as a substitute for tax, legal or investment advice.  

The information herein are not for any person in any jurisdiction or country where such distribution or availability for use would contravene any applicable law or regulation or would subject PCM to any registration or licensing requirement in such jurisdiction or country. The Products is not offered to U.S. Persons. PhillipCapital Group of Companies, including PCM, their affiliates and/or their officers, directors and/or employees may own or have positions in the Products. Any member of the PhillipCapital Group of Companies may have acted upon or used the information, analyses and opinions herein before they have been published. 

This advertisement has not been reviewed by the Monetary Authority of Singapore.  


Phillip Capital Management (S) Ltd (Co. Reg. No. 199905233W)  
250 North Bridge Road #06-00, Raffles City Tower ,Singapore 179101 
Tel: (65) 6230 8133 Fax: (65) 65383066